{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=peg-filgrastim",
    "query": {
      "intervention": "peg-filgrastim"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 274,
    "total_pages": 28,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=peg-filgrastim&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-06T13:03:40.356Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06048484",
      "title": "Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Stereotactic body radiotherapy (SBRT)",
          "type": "RADIATION"
        },
        {
          "name": "Zimberelimab",
          "type": "DRUG"
        },
        {
          "name": "Quemliclustat",
          "type": "DRUG"
        },
        {
          "name": "Etrumadenant",
          "type": "DRUG"
        },
        {
          "name": "Modified FOLFIRINOX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Gulam Manji",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2024-05-10",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-09-06T13:03:40.356Z",
      "location_count": 5,
      "location_summary": "Lake Success, New York • New York, New York • Chapel Hill, North Carolina + 2 more",
      "locations": [
        {
          "city": "Lake Success",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06048484"
    },
    {
      "nct_id": "NCT01498588",
      "title": "Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Breast Cancer",
        "Breast Tumors",
        "Cancer of the Breast",
        "Neoplasms, Breast",
        "Tumors, Breast"
      ],
      "interventions": [
        {
          "name": "Eribulin",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2011-11",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2016-10-03",
      "last_synced_at": "2026-09-06T13:03:40.356Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • Madison, Wisconsin",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01498588"
    },
    {
      "nct_id": "NCT04174742",
      "title": "Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "pegfilgrastim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 115,
      "start_date": "2019-12-17",
      "completion_date": "2041-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-09-06T13:03:40.356Z",
      "location_count": 2,
      "location_summary": "Charlotte, North Carolina • Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04174742"
    },
    {
      "nct_id": "NCT00146562",
      "title": "Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Stage I Breast Cancer",
        "Stage II Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Darbepoetin Alfa",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Harold J. Burstein, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 135,
      "start_date": "2003-07",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2023-08-02",
      "last_synced_at": "2026-09-06T13:03:40.356Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • Lowell, Massachusetts • Peabody, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Lowell",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00146562"
    },
    {
      "nct_id": "NCT01169636",
      "title": "Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "Panobinostat",
          "type": "DRUG"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2011-01-31",
      "completion_date": "2017-05-17",
      "has_results": true,
      "last_update_posted_date": "2021-01-06",
      "last_synced_at": "2026-09-06T13:03:40.356Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01169636"
    },
    {
      "nct_id": "NCT03252431",
      "title": "Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer",
        "Neutropenia"
      ],
      "interventions": [
        {
          "name": "F-627",
          "type": "DRUG"
        },
        {
          "name": "Neulasta",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EVIVE Biotechnology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 393,
      "start_date": "2018-04-12",
      "completion_date": "2020-03-05",
      "has_results": true,
      "last_update_posted_date": "2023-07-03",
      "last_synced_at": "2026-09-06T13:03:40.356Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03252431"
    },
    {
      "nct_id": "NCT01106157",
      "title": "Reversing Type 1 Diabetes After it is Established",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Anti-Thymocyte Globin (ATG)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Pegylated GCSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "12 Years to 45 Years"
      },
      "enrollment_count": 25,
      "start_date": "2010-04",
      "completion_date": "2019-07-16",
      "has_results": true,
      "last_update_posted_date": "2019-08-05",
      "last_synced_at": "2026-09-06T13:03:40.356Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Aurora, Colorado • Gainesville, Florida",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01106157"
    },
    {
      "nct_id": "NCT03107988",
      "title": "NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "Lorlatinib",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Topotecan",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim/pegfilgrastim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New Approaches to Neuroblastoma Therapy Consortium",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "1 Year to 99 Years"
      },
      "enrollment_count": 65,
      "start_date": "2017-09-05",
      "completion_date": "2025-01-31",
      "has_results": true,
      "last_update_posted_date": "2025-09-15",
      "last_synced_at": "2026-09-06T13:03:40.356Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03107988"
    },
    {
      "nct_id": "NCT00662519",
      "title": "Neulasta in Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Neulasta (Pegylated)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Mixed Meal Tolerance Test (MMTT)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Blood test",
          "type": "OTHER"
        },
        {
          "name": "DNA Test",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "12 Years to 45 Years"
      },
      "enrollment_count": 21,
      "start_date": "2008-04",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2015-04-09",
      "last_synced_at": "2026-09-06T13:03:40.356Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00662519"
    },
    {
      "nct_id": "NCT02909036",
      "title": "Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Amyloidosis"
      ],
      "interventions": [
        {
          "name": "Melphalan",
          "type": "DEVICE"
        },
        {
          "name": "Pegfilgrastim",
          "type": "DRUG"
        },
        {
          "name": "Autologous Hematopoietic Progenitor Cell Transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 46,
      "start_date": "2016-09",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2025-10-10",
      "last_synced_at": "2026-09-06T13:03:40.356Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02909036"
    }
  ]
}